Raymond James Financial Inc Akero Therapeutics, Inc. Transaction History
Raymond James Financial Inc
- $258 Billion
- Q1 2025
A detailed history of Raymond James Financial Inc transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Raymond James Financial Inc holds 36,518 shares of AKRO stock, worth $1.65 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
36,518Holding current value
$1.65 Million% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding AKRO
# of Institutions
270Shares Held
86MCall Options Held
1.02MPut Options Held
823K-
Rtw Investments, LP New York, NY7.42MShares$336 Million4.92% of portfolio
-
Janus Henderson Group PLC London, X07.07MShares$320 Million0.16% of portfolio
-
Wellington Management Group LLP Boston, MA5.94MShares$269 Million0.05% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$253 Million0.0% of portfolio
-
General Atlantic LLC New York, NY5.23MShares$237 Million7.15% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $2.1B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...